CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Glycine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00338598
NCT00338598Phase 2Completed
CompareCT.gov

Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism

Yale University·interventional·Posted Jun 20, 2006·Updated Jan 17, 2018

In Brief

A Phase 2 clinical trial evaluating Glycine and placebo for Alcoholism and Schizophrenia. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This placebo-controlled study is designed to evaluate the efficacy of glycine, an agonist of the glycine-B co-agonist site of the NMDA receptor, on alcohol consumption and craving as well as negative symptoms in schizophrenia. Glycine will decrease the rewarding action of ethanol and reduce ethanol consumption. Also, glycine will improve negative symptoms and cognitive deficits in schizophrenia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcoholism, Schizophrenia
CountriesUnited States
CollaboratorsStanley Medical Research Institute

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 20, 2006
Enrollment StartJun 1, 2003
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 12.5 yearsPosted 20.0 years ago

Interventions

Glycinedrug

Glycine, 0.8 gr per kg given in two daily doses

placebodrug